UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3391

2023

Volltextzugriff (PDF)

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.352-359

2020

Volltextzugriff (PDF)

IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications

International journal of molecular sciences, 2022-08, Vol.23 (16), p.9479

2022

Volltextzugriff (PDF)

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

Journal of investigative dermatology, 2010-07, Vol.130 (7), p.1785-1796

2010

Volltextzugriff (PDF)

Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy

JAMA dermatology (Chicago, Ill.), 2016-11, Vol.152 (11), p.1239

2016

Volltextzugriff (PDF)

How Does a Retail Environment Affect Perceived Retail Crowding?: A Study Using Virtual Reality

International journal of architectonic, spatial, and environmental design, 2022, Vol.17 (1), p.151-165

2022

Volltextzugriff (PDF)

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

Journal of the American Academy of Dermatology, 2016-12, Vol.75 (6), p.1156-1161

2016

Volltextzugriff (PDF)

Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

Dermatology and therapy, 2023-03, Vol.13 (3), p.673-688

2023

Volltextzugriff (PDF)

Nomenclature and clinical phenotypes of atopic dermatitis

Therapeutic advances in chronic disease, 2021, Vol.12, p.20406223211002979-20406223211002979

2021

Volltextzugriff (PDF)

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic

American journal of clinical dermatology, 2020-06, Vol.21 (3), p.307-311

2020

Volltextzugriff (PDF)

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

Frontiers in immunology, 2023-08, Vol.14, p.1191782-1191782

2023

Volltextzugriff (PDF)

Predictors of Local Invasion in Infiltrative Basal Cell Carcinoma: Tumour Budding Outperforms the WHO Subtyping

Acta dermato-venereologica, 2024-07, Vol.104, p.adv40172

2024

Volltextzugriff (PDF)

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2263108-2263108

2023

Volltextzugriff (PDF)

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

Dermatology and therapy, 2021-06, Vol.11 (3), p.885-905

2021

Volltextzugriff (PDF)

PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries

Acta dermato-venereologica, 2023-08, Vol.103, p.adv6532

2023

Volltextzugriff (PDF)

Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2–3

Gynecologic oncology, 2006-11, Vol.103 (2), p.631-636

2006

Volltextzugriff (PDF)

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis

American journal of clinical dermatology, 2018-02, Vol.19 (1), p.23-32

2018

Volltextzugriff (PDF)

Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan

Dermatology and therapy, 2024-01, Vol.14 (1), p.99-114

2024

Volltextzugriff (PDF)

Calibration of omnidirectional cameras in practice: A comparison of methods

Computer vision and image understanding, 2012, Vol.116 (1), p.120-137

2012

Volltextzugriff (PDF)

Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study

The Journal of dermatological treatment, 2020-05, Vol.31 (4), p.344-351

2020

Volltextzugriff (PDF)

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

Dermatology and therapy, 2023-10, Vol.13 (10), p.2171-2185

2023

Volltextzugriff (PDF)

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Drugs (New York, N.Y.), 2020-03, Vol.80 (4), p.341-352

2020

Volltextzugriff (PDF)

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

Acta dermato-venereologica, 2018-01, Vol.98 (1), p.98-102

2018

Volltextzugriff (PDF)

Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study

Dermatology and therapy, 2024-05, Vol.14 (5), p.1259-1271

2024

Volltextzugriff (PDF)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Dermatology and therapy, 2020-02, Vol.10 (1), p.133-150

2020

Volltextzugriff (PDF)

1 – 25 von 1.362

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.149)
Mit Volltextzugriff
(1.172)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy

How Does a Retail Environment Affect Perceived Retail Crowding?: A Study Using Virtual Reality

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

Nomenclature and clinical phenotypes of atopic dermatitis

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

Predictors of Local Invasion in Infiltrative Basal Cell Carcinoma: Tumour Budding Outperforms the WHO Subtyping

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries

Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2–3

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis

Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan

Calibration of omnidirectional cameras in practice: A comparison of methods

Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Suchergebnisse filtern